Join today and have your say! It’s FREE!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}

Join today with :

or

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Sign in with existing account
Please Try Again
{{ error }}

Sign In With :

or

Password Hint : {{passwordHint}}
Forgot Password?
Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Notice of Results

LSE.P.A, SMMT

Summit Therapeutics plc 
(‘Summit’ or the ‘Company’)

Summit Therapeutics to Report Financial Results for the Second Quarter and Half Year Ended 31 July 2019 on 11 October 2019

Oxford, UK, and Cambridge, MA, US, 10 October 2019 – Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM) a leader in new mechanism antibiotic innovation, will announce its financial results for the second quarter and half year ended 31 July 2019 on 11 October 2019.

Summit will host a conference call the same day at 1:00pm BST / 8:00am EDT. Conference call information will be included in the second quarter and half year results press release, and a replay of the call will also be available through the Company’s website, www.summitplc.com.

About Summit Therapeutics
Summit Therapeutics is a leader in antibiotic innovation. Our new mechanism antibiotics are designed to become the new standards of care for the benefit of patients and create value for payors and healthcare providers. We are currently developing new mechanism antibiotics for infections caused by C. difficile, N. gonorrhoeae and Enterobacteriaceae and are using our proprietary Discuva Platform to expand our pipeline. For more information, visit www.summitplc.com and follow us on Twitter @summitplc.

Contacts

Summit  
Glyn Edwards / Richard Pye (UK office)Tel:44 (0)1235 443 951
Michelle Avery (US office) +1 617 225 4455
   
Cairn Financial Advisers LLP (Nominated Adviser)Tel:+44 (0)20 7213 0880
Liam Murray / Tony Rawlinson  
   
N+1 Singer (Joint Broker)Tel:+44 (0)20 7496 3000
Aubrey Powell / Jen Boorer, Corporate Finance
Tom Salvesen, Corporate Broking
  
   
Bryan Garnier & Co Limited (Joint Broker)Tel:+44 (0)20 7332 2500
Phil Walker / Dominic Wilson

 
  
MSL Group (US)Tel:+1 781 684 6652
Erin Anthoine summit@mslgroup.com
   
Consilium Strategic Communications (UK)Tel:+44 (0)20 3709 5700
Mary-Jane Elliott / Sue Stuart / Sukaina Virji summit@consilium-comms.com
Lindsey Neville  

-END-

Primary Logo





×

StockTalk
Get our FREE StockTalk Investor Guides by sector as they are released!

Stay on top of sector specific news, get industry leaders insights and our best content, delivered to your email.

You are already a member! Please enter your password to sign in.